Ondine Biopharma Corporation is dedicated to the development of non-antibiotic anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections. The Company is focused on the development and commercialization of its patented light activated technology, Photodisinfection (PDD), for multiple applications. PDD provides antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. Ondine launched is first PDD product Periowave in 2006. Periowave is used as an adjunctive therapy for the treatment of chronic adult periodontitis (gum disease). In June 2009 Ondine sold its Dental Healthcare Business to PDT Inc.
